Key result
Intracardiac thrombus developed in 6% of children with dilated cardiomyopathy, all of whom had an LVEF >30% and were not receiving antiaggregant therapy, while mean LVEF did not differ between those with and without thrombus.
Why the study?
Does antiaggregant therapy prevent intracardiac thrombus in children with dilated cardiomyopathy?
Cohort (n=83)
No
Does antiaggregant therapy prevent intracardiac thrombus in children with dilated cardiomyopathy?
Intracardiac thrombus can develop in children with dilated cardiomyopathy even with LVEF >30%, suggesting a potential role for prophylactic antithrombotic therapy at diagnosis regardless of LVEF.
Answers are grounded in this paper and cite their sources.
Thrombus risk in pediatric DCM may occur with LVEF >30% without antiaggregants; hypothesis-generating for early prophylaxis, pending prospective trials.
OBJECTIVES: The risk of fatal pulmonary and systemic thromboembolism is high in patients with dilated cardiomyopathy with cardiac thrombus. This study was planned to reveal the efficacy of antiaggregant therapy in patients with low left ventricular systolic ejection fraction (LVEF). STUDY DESIGN: The present study retrospectively reviewed the files of 83 cases (42 males, 41 females) with dilated cardiomyopathy who were followed between June 2004 and December 2011. RESULTS: Intracardiac thrombus was detected in five (6%) cases; of these five patients, dilated cardiomyopathy was idiopathic in four and secondary to chronic renal failure in one. The cases were followed for a mean of 33.6±35.6 months (3 days-168 months). Mean LVEF on transthoracic echocardiography was found as 35.2±2.7% (32-38%) for the cases with intracardiac thrombus, whereas it was 34.7±11.0% (10-55%) for the cases without intracardiac thrombus. No statistically significant difference was found between the groups (p=0.910). Cases with LVEF ≤30% were routinely receiving acetylsalicylic acid at antiaggregant dose. CONCLUSION: We think that prophylactic antithrombotic/antiaggregant therapy should be started at the time of diagnosis even in patients with LVEF >30%, as thrombus development was seen in cases with LVEF >30% without any antiaggregant therapy.
No takes yet. Share an insight, caveat, or question.
Ahmet İrdem (2014) conducted a cohort in Dilated cardiomyopathy (n=83). Intracardiac thrombus vs. No intracardiac thrombus was evaluated on Mean Left Ventricular Ejection Fraction (LVEF) (p=0.910). Intracardiac thrombus developed in 6% of children with dilated cardiomyopathy, all of whom had an LVEF >30% and were not receiving antiaggregant therapy, while mean LVEF did not differ between those with and without thrombus.
Synapse has enriched 10 related papers. Consider them for comparative context: